Tasly Mauna Kea Medical Engineering Technology Co. Ltd will expand reach of Cellvizio in China and launch a dedicated platform for neurosurgical applications worldwide <\/i><\/b><\/p>\n
Mauna Kea Technologies and Tasly Pharmaceutical Group today announced the achievement of a new key milestone in their strategic partnership.<\/p>\n
Tasly Mauna Kea Medical Engineering Technology Co. Ltd., <\/i>based in the Zheijang province of China, is now legally incorporated with registered capital of RMB 250 million (EUR 35 million1<\/sup>). Tasly Mauna Kea Medical Engineering Technology Co. Ltd. <\/i>will serve as the exclusive commercial platform for expanding the reach of Cellvizio into the Chinese domestic market and will launch a dedicated platform for neurosurgical applications worldwide.<\/p>\n Jing Su, MD, General Manager of Tasly Pharmaceutical Group, commented: “We couldn’t be more enthusiastic about our Joint Venture’s prospects in China and beyond, thanks to the great resources we are collectively endowing it with. We look forward to the upcoming success of this partnership based on synergies between Mauna Kea’s unique Cellvizio platform, Tasly’s commercial strength and its expertise in pharmaceutical development.<\/i>” <\/i><\/p>\n Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, concluded: “This is an important accomplishment toward advancing Mauna Kea Technologies’ partnership with Tasly, which will allow us to achieve our shared commercial ambitions. I am excited about Cellvizio’s roadmap in China and the opportunity to benefit from Tasly’s significant scale in this key market.”<\/i><\/p>\n [1] As of November 6, 2022.<\/span><\/p>\n <\/p>\n
\n